AGEN2034, a novel anti-PD-1 antibody that combines effectively with CTLA-4 pathway blockade to enhance T cell activity Meeting Abstract
| Authors: | Chand, D.; Savitsky, D.; Gonzalez, A.; Clarke, C.; Schuster, A.; Drouin, E. E.; Waight, J. D.; Mundt, C.; Ritter, G.; Merghoub, T.; Schaer, D.; Homlgaard, R. B.; Zappasodi, R.; van Dijk, M.; Buell, J. S.; Cuillerot, J. M.; Stein, R.; Wilson, N. S. |
| Abstract Title: | AGEN2034, a novel anti-PD-1 antibody that combines effectively with CTLA-4 pathway blockade to enhance T cell activity |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-11-07 |
| Start Page: | 87 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0288-4 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P312 -- Rikke B. Holmgaard's last name is misspelled on the original publication |
Altmetric
Citation Impact
BMJ Impact Analytics
